Latest Spasmodic torticollis Stories
GREENSBORO, N.C., March 30, 2011 /PRNewswire/ -- Merz Pharmaceuticals, LLC announced today that the Centers for Medicare and Medicaid Services (CMS) has granted a unique Healthcare Common Procedure Coding System (HCPCS) billing code, Q2040, for XeominÂ® (incobotulinumtoxinA).
Implanting electrodes into a pea-sized part of the brain can dramatically improve life for people with severe cervical dystonia â€“ a rare but extremely debilitating condition that causes painful, twisting neck muscle spasms.
GREENSBORO, N.C., March 8, 2011 /PRNewswire/ -- Merz Pharmaceuticals today announced the launch of two programs to provide financial assistance to patients for their treatment with XeominÂ® (incobotulinumtoxinA).
GREENSBORO, N.C., Feb.
Parkinson's disease symptoms begin subtly and worsen as damage to certain brain cells continues.
A new study by researchers at the Faculty of Kinesiology, University of Calgary, is raising questions about the therapeutic use of botulinum toxin A.
GREENSBORO, N.C., Nov.
GREENSBORO, N.C., Oct. 5 /PRNewswire/ -- Merz Pharmaceuticals today announced that XeominÂ® (incobotulinumtoxinA), a new botulinum toxin type A for the treatment of adults with cervical dystonia (CD)or blepharospasm, is now commercially available in the U.S. XEOMIN was approved by the U.S.
GREENSBORO, N.C., Aug. 2 /PRNewswire/ -- Merz Pharmaceuticals today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved XeominÂ® (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm.
PHOENIX, April 21 /PRNewswire/ -- One of the world's most fashionable beauty treatments is gaining popularity for something other than the war on wrinkles.
- A young chicken: also used as a pet name for children.